Skip to content
Register Sign in Wishlist

Recombinant Antibodies for Immunotherapy

$99.00 USD

G. Winter, G. Beste, D. Lowe, V. Molkenthin, S. Knackmuss, I. Klagge, A. Jakobovits, A. Murphy, J. Saldanha, P. Stas, J. Pletinckx, Y. Gansemans, I. Lasters, F. Carr, M. Baker, R. Stewart, C. Webster, G. Lazar, A. Chamberlain, P. Brünker, P. Sondermann, P. Umana, D. King, C. Kousparou, A. Epenetos, N. Courtenay-Luck, D. Jones, F. Le Gall, M. Little, S. Muyldermans, F. Rüker, G. Wozniak-Knopp, A. Plueckthun, S. Heywood, D. Humphreys, J. Andersen, I. Sandlie, J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, D. Loo, H. Lowe, S. Sharma, K. Bagshawe, D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, M. Rosenzweig, C. Bourrilly
View all contributors
  • Date Published: September 2009
  • availability: This ISBN is for an eBook version which is distributed on our behalf by a third party.
  • format: Adobe eBook Reader
  • isbn: 9780511590689

$ 99.00 USD
Adobe eBook Reader

You will be taken to ebooks.com for this purchase
Buy eBook Add to wishlist

Other available formats:
Hardback


Looking for an inspection copy?

This title is not currently available on inspection

Description
Product filter button
Description
Contents
Resources
Courses
About the Authors
  • Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.

    • Represents perhaps the most comprehensive overview of the field recombinant antibodies including the most recent innovations
    • Provides excellent market analysis of this field presented by a director of ABN AMRO, which is a special feature of the book that is difficult to equal
    • Includes contributions from prominent scientists who laid the groundwork for this field
    Read more

    Customer reviews

    Not yet reviewed

    Be the first to review

    Review was not posted due to profanity

    ×

    , create a review

    (If you're not , sign out)

    Please enter the right captcha value
    Please enter a star rating.
    Your review must be a minimum of 12 words.

    How do you rate this item?

    ×

    Product details

    • Date Published: September 2009
    • format: Adobe eBook Reader
    • isbn: 9780511590689
    • contains: 50 b/w illus. 11 colour illus. 32 tables
    • availability: This ISBN is for an eBook version which is distributed on our behalf by a third party.
  • Table of Contents

    Part I. Introduction:
    1. Past, present and future of recombinant antibodies G. Winter
    Part II. Generation and Screening of Antibody Libraries:
    2. Antibody libraries from naïve V gene sources G. Beste and D. Lowe
    3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss
    Part III. Transgenic Human Antibody Repertoires:
    4. The generation and screening of synthetic antibody libraries I. Klagge
    5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits
    6. Transgenic chimeric antibodies A. Murphy
    Part IV. Humanised Antibodies:
    7. Humanization of recombinant antibodies J. Saldanha
    8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters
    9. In vitro screening for antibody immunogenicity F. Carr and M. Baker
    Part V. Antibody Effector Function:
    10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster
    11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain
    12. Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P. Umana
    Part VI. Arming Antibodies:
    13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King
    14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos
    15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones
    Part VII. Antibody Fragments:
    16. Alternative antibody formats F. Le Gall and M. Little
    17. Single domain antibodies S. Muyldermans
    18. Engineering of non-CDR loops in immunoglobulin domains F. Rüker and G. Wozniak-Knopp
    Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins:
    19. Alternative antibody scaffolds A. Plueckthun
    Part IX. Prolongation of Serum Half Life:
    20. Polymer fusions to increase antibody half lives: PEGylation and other modifications S. Heywood and D. Humphreys
    21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie
    Part X. Current Therapeutic Antibodies and Novel Developments:
    22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo
    23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe
    24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig
    Part XI. Market Overview and Outlook:
    25. Antibody therapeutics: business achievements and business outlook C. Bourrilly.

  • Editor

    Melvyn Little, Affimed Therapeutics AG
    Melvyn Little's research group at the German Cancer Research Center (DKFZ) in Heidelberg was one of the first to develop methods for making and screening antibody libraries. After co-founding Affitech (Oslo, Norway) in 1997, he left the DKFZ in 2000 to found Affimed Therapeutics, a biotechnology company in Heidelberg specializing in the isolation and engineering of human antibodies to treat various diseases, especially cancer. He has been an extracurricular Professor of Biochemistry at the University of Heidelberg since 1986.

    Contributors

    G. Winter, G. Beste, D. Lowe, V. Molkenthin, S. Knackmuss, I. Klagge, A. Jakobovits, A. Murphy, J. Saldanha, P. Stas, J. Pletinckx, Y. Gansemans, I. Lasters, F. Carr, M. Baker, R. Stewart, C. Webster, G. Lazar, A. Chamberlain, P. Brünker, P. Sondermann, P. Umana, D. King, C. Kousparou, A. Epenetos, N. Courtenay-Luck, D. Jones, F. Le Gall, M. Little, S. Muyldermans, F. Rüker, G. Wozniak-Knopp, A. Plueckthun, S. Heywood, D. Humphreys, J. Andersen, I. Sandlie, J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, D. Loo, H. Lowe, S. Sharma, K. Bagshawe, D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, M. Rosenzweig, C. Bourrilly

Sign In

Please sign in to access your account

Cancel

Not already registered? Create an account now. ×

Sorry, this resource is locked

Please register or sign in to request access. If you are having problems accessing these resources please email lecturers@cambridge.org

Register Sign in
Please note that this file is password protected. You will be asked to input your password on the next screen.

» Proceed

You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner www.ebooks.com. Please see the permission section of the www.ebooks.com catalogue page for details of the print & copy limits on our eBooks.

Continue ×

Continue ×

Continue ×

Find content that relates to you

Join us online

This site uses cookies to improve your experience. Read more Close

Are you sure you want to delete your account?

This cannot be undone.

Cancel

Thank you for your feedback which will help us improve our service.

If you requested a response, we will make sure to get back to you shortly.

×
Please fill in the required fields in your feedback submission.
×